<DOC>
	<DOCNO>NCT00006369</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use ERA-923 may fight breast cancer block uptake estrogen tumor cell . PURPOSE : Randomized phase II trial study effectiveness ERA-923 treating postmenopausal woman metastatic breast cancer long respond tamoxifen .</brief_summary>
	<brief_title>ERA-923 Treating Postmenopausal Women With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy 2 dose level ERA-923 postmenopausal patient metastatic breast cancer refractory tamoxifen . II . Determine safety plasma level drug patient . III . Determine impact quality life patient drug . OUTLINE : This randomize , double blind , multicenter study . Patients randomize one two treatment arm receive different dos ERA-923 . Patients receive oral ERA-923 daily 48 week absence disease progression unacceptable toxicity . Quality life assess baseline ; week 4 , 8 , 16 , 24 , 32 , 40 , 48 ; 4 week last dose . Patients follow 4 week every 3 month thereafter . PROJECTED ACCRUAL : At total 36-100 patient ( 18-50 per arm ) accrue study within 1 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic breast cancer Prior tamoxifen therapy failure within 1 year study define follow : Prior tamoxifen therapy metastatic disease prior response progression disease still treatment within 1 year last treatment Prior adjuvant tamoxifen therapy minimum 2 year subsequent progression disease still treatment within 1 year last treatment Postmenopausal Must amenorrheic least 12 month Removal ovary chemotherapy induce menopause allow At least 1 bideminsionally measurable lesion No disease restrict bone No symptomatic CNS metastasis untreated surgery radiotherapy Hormone receptor status : Estrogen progesterone receptor positive PATIENT CHARACTERISTICS : Age : Not specify Menopausal status : Postmenopausal Performance status : ECOG 02 Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin great 9.0 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 3 time ULN ( great 5 time ULN liver metastasis present ) PT PTT great 1.25 time ULN Renal : Creatinine great 1.5 time ULN Cardiovascular : No deep vein thrombosis , retinal vein thrombosis , stroke within past year No unstable angina myocardial infarction within past 6 month Pulmonary : No pulmonary embolism within past year Other : Not pregnant nursing No major illness condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent trastuzumab ( Herceptin ) Chemotherapy : No 2 prior chemotherapy regimen , include trastuzumab One regimen adjuvant set one metastatic setting OR Two regimen metastatic set No concurrent chemotherapy Endocrine therapy : See Disease Characteristics At least 6 month since prior raloxifene osteoporosis No prior hormonal , antiestrogen , aromatase inhibitor tamoxifen breast cancer At least 4 week since prior tamoxifen No concurrent hormonal replacement therapy , antiestrogens ( include raloxifene ) , aromatase inhibitor , systemic steroid ( except physiologic replacement dos ) Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : At least 4 week since prior investigational drug No concurrent warfarin exept low dose warfarin port maintenance No concurrent investigational agent No concurrent immunosuppressive therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>